Coronavirus Infection, Covid19, SARS-CoV Infection, Severe Acute Respiratory Syndrome
Conditions
Keywords
SARS-CoV-2, COVID-19, Serology, French Guiana
Brief summary
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.
Detailed description
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana. This study is a interventional study that present minimal risks and constraints. The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.
Interventions
PROCEDUREBlood sample
Blood sample
Sponsors
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Laboratoire de biologie médicale de Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
Eurofins
Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
Institut Pasteur
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19; * State of health compatible with a blood sample as defined in the protocol
Exclusion criteria
* Inability to consent * Person under guardianship or curatorship * Known pathology or a health problem contraindicated with the collect of blood sample.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of the COVID-19 immunity of the population | 1 year | The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the level of asymptomatic and pauci-symptomatic infections | 1 year | The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population |
Countries
French Guiana
Outcome results
None listed